Viking Therapeutics delivered a disappointing earnings report on October 22, revealing a quarterly loss of $0.81 per share that fell substantially short of ...
With a new generation of weight-loss drugs entering Indian markets, spelling hope for many, The Indian Express tracks the ...
New Scripps Research trial will explore the effects of Lilly’s GLP-1 drug on reducing the symptoms of the debilitating disease.
Eli Lilly delivered a stunning financial performance that exceeded even the most optimistic market expectations, driven by unprecedented demand for its ...
El ensayo clínico, que busca reclutar a 1000 pacientes con COVID persistente en todo el país, explorará cómo la autoadministración de tirzepatida, el agonista del GLP-1 de Eli Lilly comercializado ...
Investor's Business Daily on MSN
S&P 500 Giants JPMorgan, Eli Lilly Lead Five Stocks Near Buy Points
S &P 500 giants Eli Lilly LLY and JPMorgan Chase JPM are stocks to watch this coming week. So is Interactive Brokers IBKR, ...
The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback